A Study of LDGraft In Single Level Lumbar Interbody Fusion (AMBITION)
The objective of the study is to evaluate the safety and effectiveness of LDGraft (investigational device) when applied in a lumbar interbody fusion procedure in the treatment of patients with lumbar Degenerative Disc Disease (DDD).
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Robyn Cochrane
- 電話番号:+44115 7738447
- メール:rcochrane@locatebio.com
研究場所
-
-
-
Tbilisi、グルジア、44600
- 募集
- West Georgia Medical Center
-
コンタクト:
- Study Coordinator
-
Tbilisi、グルジア、4600
- 募集
- JSC Georgian Clinics Kutaisi Referral Hospital
-
コンタクト:
- Study Coordinator
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Skeletally mature adults ≥22 and ≤80 years at the time of surgery
- Willing and able to give written informed consent and comply with study protocol and postoperative management program
- Degenerative disc disease of the lumbosacral spine in one level requiring fusion confirmed by patient history and radiographic imaging
- Preoperative Oswestry Disability Index score ≥ 35
- Participant has not responded to conservative treatment (e.g. medications, injections, physical therapy, etc.) for a period of 6 months
Exclusion Criteria:
- Previous lumbar spine instrumentation (i.e., anterior disc replacement, interspinous device) or a previous interbody fusion procedure in the lumbar spine
- More than one level lumbar spine level requiring fusion
- Three or more contiguous lumbar spine levels requiring decompression
- Known hypersensitivity or allergy to any components of the study treatments inclusive of hypersensitivity or allergy to any BMP-2 type recombinant proteins or peptides.
- Pregnant, planning to become pregnant during the follow-up time period, or breast-feeding women
- Presence of active malignancy
- Requires bone growth stimulation in the lumbar spine
- Active local or systemic infection
- Spondylolisthesis greater than Grade 2 (50% translation)
- Currently smoking or using nicotine products, including e-cigarette products (e.g., vaping)
- Any degenerative muscular or neurological condition that would interfere with evaluation of outcomes, including but not limited to Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis
- Any medical condition requiring treatment with any drug known to potentially interfere with bone/soft tissue healing or receiving radiation therapy that is expected to continue for the duration of the study
- Body Mass Index > 40
- Insulin-dependent diabetes mellitus
- Osteopenia or osteoporosis of the spine
- Any secondary causes of osteoporosis or other conditions known to adversely affect osteogenesis
- Participation in another investigational study within 30 days prior to surgery for investigational devices, or within the last three months for investigational drugs
- Current or recent history of chemical/alcohol abuse or dependency using standard medical definition of DSM-5 code
- In the opinion of the investigator, the participant has a behavioral, cognitive, social or medical problem that may interfere with the assessment of the safety or effectiveness of the product
- Radiographically compromised vertebral bodies at the index level due to current or past trauma
- Currently a prisoner
- Involved in active litigation relating to his/her spinal condition or workers compensation claimants.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:LDGraft
|
LDGraft (b-TCP / rhBMP-2) bone graft substitute |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Secondary Surgical Intervention (SSI)
時間枠:6-month and 12-month follow up
|
No index level secondary surgical intervention reported |
6-month and 12-month follow up
|
|
Radiographic Fusion
時間枠:6-month and 12-month follow up
|
Radiographic fusion derived from bridging bone, angular motion and translational motion assessment via CT |
6-month and 12-month follow up
|
|
Oswestry Disability Index (ODI) Improvement
時間枠:6-month and 12-month follow up
|
At least 15 point improvement in ODI compared to baseline |
6-month and 12-month follow up
|
|
No new or worsening lumbar spine neurological condition
時間枠:6-month and 12-month follow up
|
No new or worsening lumbar spine neurological condition compared to baseline |
6-month and 12-month follow up
|
|
No Serious Device Related Adverse Events
時間枠:6-month and 12-month follow up
|
6-month and 12-month follow up
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Visual Analog Score (VAS) Leg Improvement
時間枠:6-week, 3-month, 6-month and 12-month follow up
|
20mm improvement compared to baseline |
6-week, 3-month, 6-month and 12-month follow up
|
|
Visual Analog Score (VAS) Back Improvement
時間枠:6-week, 3-month, 6-month and 12-month follow up
|
20mm improvement compared to baseline |
6-week, 3-month, 6-month and 12-month follow up
|
|
Oswestry Disability Index (ODI) Change
時間枠:6-week, 3-month, 6-month and 12 month follow up
|
Mean change over time intervals |
6-week, 3-month, 6-month and 12 month follow up
|
|
Visual Analog Score (VAS) Leg Change
時間枠:6-week, 3-month, 6-month and 12-month follow up
|
Mean change over time intervals |
6-week, 3-month, 6-month and 12-month follow up
|
|
Visual Analog Score (VAS) Back Change
時間枠:6-week, 3-month, 6-month and 12-month follow up
|
Mean change over time intervals |
6-week, 3-month, 6-month and 12-month follow up
|
|
Quality of Life & Satisfaction
時間枠:6-week, 3-month-, 6-month and 12-month follow up
|
Evaluation of Quality of Life & Satisfaction survey results |
6-week, 3-month-, 6-month and 12-month follow up
|
|
Radiogrpahic Outcomes
時間枠:6-week, 3-month, 6-month and 12-month follow up
|
Radiographic outcomes as defined by Image Review Charter |
6-week, 3-month, 6-month and 12-month follow up
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- CI-002
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。